Indication: short-term management of insomnia
Adult, PO
Immediate release: 5-10 mg at bedtime. Max: 10 mg/day; extended release 6.25-12.5 mg at bedtime. Max: 12.5 mg/day. Max duration: 4 wk including tapering.
Adverse drug reactions: atypical thinking and behaviour, hallucination, nightmare, somnolence, somnambulism, headache, nausea, vomiting, dizziness, vertigo, drowsiness, asthenia, ataxia, rebound insomnia, amnesia, etc.
See reference for details. CIMS Drug Information System. Internet. Accessed on January 10, 2016.